Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Dixon Kaufman

Transplant Surgery Madison, WI Medical Doctor

NPI 1871527176 CMS profile 1156975

600 Highland Ave, Uw Hospital, Madison, WI 53792

Open in the dashboard

General payments

$14,627

10 records reported · program years 2020–2025

Research payments

$4,608

Paid to them · 8 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$205,980 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Dixon Kaufman of Madison, WI is reported in the CMS Open Payments database as having received $14,627 across 10 general payments and $4,608 in research payments paid to them. Separately, studies naming them as principal investigator received $205,980 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,895 1
2023 General $50 1
2022 General $4,356 2
2021 General $7,326 6
2021 Research $733 2
2020 Research $3,874 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dixon Kaufman
  • Transplant Surgery median
  • Middle half of Transplant Surgery
  • National median

In program year 2025, general payments to Dixon Kaufman were reported at $2,895. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.

Show as a table
Year Dixon Kaufman Transplant Surgery median Middle half National median
2019 $0 $203 $77–$1,249 $163
2020 $0 $149 $52–$1,366 $114
2021 $7,326 $168 $73–$2,008 $132
2022 $4,356 $213 $94–$1,464 $149
2023 $50 $262 $93–$1,458 $160
2024 $0 $354 $126–$2,252 $164
2025 $2,895 $421 $116–$2,169 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Veloxis Pharmaceuticals, Inc. $7,026 6 payments
  2. Sanofi-Aventis U.S. LLC $4,706 3 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $2,895 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $8,895 2 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,706 3 payments
  3. Travel and Lodging $706 3 payments
  4. Food and Beverage $320 2 payments
Products named General payments · program years 2020–2025
  1. Envarsus Immunosuppresant $6,976 5 payments
  2. THYMOGLOBULIN $350 1 payment
  3. LEMTRADA $350 1 payment
  4. ENVARSUS Transplantation $50 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. Astellas Pharma Global Development $4,608 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

298

Median for General Surgery: 59

Drug cost

$211,141

Median for General Surgery: $393

Branded share of claims

62.4%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prevymis Letermovir Brand 30 $205,868
Mycophenolic Acid Mycophenolate Sodium Brand 11 $2,155
Valganciclovir Hcl Generic 16 $1,709
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 145 $508
Nystatin Generic 11 $276
Acyclovir Generic 23 $196
Doxazosin Mesylate Generic 17 $185
Prednisone Generic 30 $182
Pantoprazole Sodium Generic 15 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$46,170

Medicare's payments for the services billed

Medicare patients

59

Average age 53

Services billed

285

23 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 69%
Depression 44%
Ischemic heart disease 34%
Heart failure 27%
Arthritis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Surgery in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record